Physician

Abdulhadi Quadri, M.D.

According to 2025 Medicare claims, Abdulhadi Quadri, M.D. (NPI: 1811981913) practices gastroenterology in the Newark, NJ market, with the plurality of this provider's patient population coming from Union, NJ. This provider's primary affiliated billing organization is GLOBAL GASTROENTEROLOGY LLC (NPI: 1740998186; TIN: 883116685) and primary practice location at 08902-4836. Quadri is affiliated with the IHCI ACO LLC (ACO ID: A4931) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Quadri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 136 traditional Medicare patients, billed 393 HCPCS/CPT codes, and received $50,684 in Medicare payments. The top billing code was 43239 (Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope). Part D data shows 1,701 prescription claims across 324 beneficiaries totaling $398,598 in drug costs, led by Ozempic (Semaglutide). 2016 DME data shows 37 claims. Open Payments data shows 7 records totaling $117. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $499,336 to $50,684. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $973,039 to $398,598. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	618	6,487	$499,336
2016	538	3,659	$276,209
2017	347	643	$72,378
2018	125	192	$19,597
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	25	49	$5,372
2022	48	125	$14,795
2023	86	265	$39,434
2024	136	393	$50,684

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	200	1,636	$973,039
2016	193	1,383	$831,570
2017	190	633	$413,307
2018	72	264	$216,203
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	54	185	$17,856
2022	69	229	$32,002
2023	172	519	$192,938
2024	324	1,701	$398,598

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	37	$5,781
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	35	36	$179
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	42	42	$155
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	20	20	$127
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	60	118	$99
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	17	18	$93

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	151	5,270	$159,901
Rezdiffra	Resmetirom	23	690	$90,303
Mounjaro	Tirzepatide	42	1,266	$48,646
Zenpep	Lipase/Protease/Amylase	15	480	$23,912
Creon	Lipase/Protease/Amylase	16	492	$21,665

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$117	Salix Pharmaceuticals, a division of Bausch Health US, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdulhadi Quadri, M.D.?

Tedicare shows public-source Medicare data for Abdulhadi Quadri, M.D. (NPI 1811981913), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdulhadi Quadri, M.D. have ACO affiliation data?

Abdulhadi Quadri, M.D. is shown with ACO affiliation data for IHCI ACO LLC (MSSP, ACO ID A4931) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Abdulhadi Quadri, M.D.?

Abdulhadi Quadri, M.D. is linked to GLOBAL GASTROENTEROLOGY LLC (billing NPI 1740998186) in the available physician profile data.

Does Abdulhadi Quadri, M.D. have Open Payments data?

Abdulhadi Quadri, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.